Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Huoxue Formula (JPHX) is a traditional Chinese medicine (TCM) herbal formula developed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD). It is composed of eight Chinese herbs: *Atractylodes macrocephala* (Bai Zhu), *Salvia miltiorrhiza* (Dan Shen), *Citrus aurantium* (Zhi Qiao), *Paeonia lactiflora* (Bai Shao), *Pueraria lobata* (Ge Gen), *Alisma orientalis* (Ze Xie), *Schisandra chinensis* (Wu Wei Zi), and *Curcuma longa* (Jiang Huang). JPHX has been shown to reduce liver fat content, alleviate hepatic steatosis, and improve liver injury. Its therapeutic mechanisms are associated with the regulation of the PPAR and MAPK signaling pathways, as well as the inhibition of JNK phosphorylation and the suppression of caspase-3 and caspase-7 activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Huoxue Formula.